Search Results - "DOWSETT, M"

Selecting patients for extended adjuvant endocrine therapy by Dowsett, M

Get full text

Developments in Ki67 and other biomarkers for treatment decision making in breast cancer by Sheri, A, Dowsett, M

“…Estrogen receptor (ER) and HER2 are well established as predictive markers for treatment benefit, although methodological deficiencies can still affect their…”
Get full text

SP003 Pathology challenges for biology-driven trials: The Ki67 experience by Dowsett, M

Get full text

PG 8.02 Neoadjuvant endocrine therapy: patient selection, treatment duration and surrogate endpoints by Dowsett, M

Get full text

Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy by Sheri, A., Smith, I.E., Johnston, S.R., A'Hern, R., Nerurkar, A., Jones, R.L., Hills, M., Detre, S., Pinder, S.E., Symmans, W.F., Dowsett, M.

“…The purpose of this study was (i) to test the hypothesis that combining Ki67 with residual cancer burden (RCB) following neoadjuvant chemotherapy, as the…”
Get full text

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group by Dowsett, Mitch, Nielsen, Torsten O., A'Hern, Roger, Bartlett, John, Coombes, R. Charles, Cuzick, Jack, Ellis, Matthew, Henry, N. Lynn, Hugh, Judith C., Lively, Tracy, McShane, Lisa, Paik, Soon, Penault-Llorca, Frederique, Prudkin, Ljudmila, Regan, Meredith, Salter, Janine, Sotiriou, Christos, Smith, Ian E., Viale, Giuseppe, Zujewski, Jo Anne, Hayes, Daniel F.

“…Uncontrolled proliferation is a hallmark of cancer. In breast cancer, immunohistochemical assessment of the proportion of cells staining for the nuclear…”
Get full text

Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer by Dowsett, M

“…Hormonal therapy leads to improved survival in oestrogen receptor (ER) positive early breast cancer and long-term responses in advanced disease. However,…”
Get full text

Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors by Kendall, A., Dowsett, M., Folkerd, E., Smith, I.

“…Background: Aromatase inhibitors (AI) are increasingly used in early breast cancer and there is a growing interest in associated long-term side-effects of…”
Get full text

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype by Gnant, M., Sestak, I., Filipits, M., Dowsett, M., Balic, M., Lopez-Knowles, E., Greil, R., Dubsky, P., Stoeger, H., Rudas, M., Jakesz, R., Ferree, S., Cowens, J.W., Nielsen, T., Schaper, C., Fesl, C., Cuzick, J.

“…In the adjuvant treatment of hormone receptor-positive (HR+) breast cancer, variables like tumour size, grade and nodal status have great impact on therapy…”
Get full text

Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies by Key, T J, Appleby, P N, Reeves, G K, Travis, R C, Alberg, A J, Barricarte, A, Berrino, F, Krogh, V, Sieri, S, Brinton, L A, Dorgan, J F, Dossus, L, Dowsett, M, Eliassen, A H, Fortner, R T, Hankinson, S E, Helzlsouer, K J, Hoff man-Bolton, J, Comstock, George W, Kaaks, R, Kahle, L L, Muti, P, Overvad, K, Peeters, P H M, Riboli, E, Rinaldi, S, Rollison, D E, Stanczyk, F Z, Trichopoulos, D, Tworoger, S S, Vineis, P

“…Summary Background Associations between circulating concentrations of oestrogens, progesterone, and androgens with breast cancer and related risk factors in…”
Get full text

Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance by Plaza-Menacho, I, Morandi, A, Robertson, D, Pancholi, S, Drury, S, Dowsett, M, Martin, L-A, Isacke, C M

“…Endocrine therapy is the main therapeutic option for patients with estrogen receptor (ERα)-positive breast cancer. Resistance to this treatment is often…”
Get full text

Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC) by Arnedos, M., Nerurkar, A., Osin, P., A'Hern, R., Smith, I.E., Dowsett, M.

“…Analysis of estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC) is increasingly being conducted in core needle…”
Get full text

Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study by Yeo, B, Zabaglo, L, Hills, M, Dodson, A, Smith, I, Dowsett, M

“…Background: Most oestrogen receptor (ER)-positive early breast cancer diagnosed today is highly curable with multimodality treatment. Systemic adjuvant…”
Get full text

Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies by HORMONES, Endogenous

“…Background: Breast cancer risk for postmenopausal women is positively associated with circulating concentrations of oestrogens and androgens, but the…”
Get full text

Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer by Barton, S, Zabaglo, L, A'Hern, R, Turner, N, Ferguson, T, O'Neill, S, Hills, M, Smith, I, Dowsett, M

“…Background: The immunohistochemical (IHC) 4+C score is a cost-effective prognostic tool that uses clinicopathologic factors and four standard IHC assays:…”
Get full text

Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics by Ellis, Matthew J., Tao, Yu, Luo, Jingqin, A'Hern, Roger, Evans, Dean B., Bhatnagar, Ajay S., Chaudri Ross, Hilary A., von Kameke, Alexander, Miller, William R., Smith, Ian, Eiermann, Wolfgang, Dowsett, Mitch

“…Background Understanding how tumor response is related to relapse risk would help clinicians make decisions about additional treatment options for patients who…”
Get full text

Twenty-Year Follow-up of the Royal Marsden Randomized, Double-Blinded Tamoxifen Breast Cancer Prevention Trial by Powles, Trevor J., Ashley, Sue, Tidy, Alwynne, Smith, Ian E., Dowsett, Mitch

“…Background Several clinical trials have reported an early reduction in breast cancer incidence in healthy women using tamoxifen to reduce their risk of breast…”
Get full text

Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status by Dowsett, M., Houghton, J., Iden, C., Salter, J., Farndon, J., A'Hern, R., Sainsbury, R., Baum, M.

“…Background: Most women with oestrogen receptor (ER) positive primary breast cancer receive adjuvant tamoxifen after surgery. The measurement of tumour…”
Get full text

The AURORA initiative for metastatic breast cancer by Zardavas, D, Maetens, M, Irrthum, A, Goulioti, T, Engelen, K, Fumagalli, D, Salgado, R, Aftimos, P, Saini, K S, Sotiriou, C, Campbell, P, Dinh, P, von Minckwitz, G, Gelber, R D, Dowsett, M, Di Leo, A, Cameron, D, Baselga, J, Gnant, M, Goldhirsch, A, Norton, L, Piccart, M

“…Metastatic breast cancer is one of the leading causes of cancer-related mortality among women in the Western world. To date most research efforts have focused…”
Get full text

Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment by Drury, S C, Detre, S, Leary, A, Salter, J, Reis-Filho, J, Barbashina, V, Marchio, C, Lopez-Knowles, E, Ghazoui, Z, Habben, K, Arbogast, S, Johnston, S, Dowsett, M

“…Development of resistance to the antioestrogen tamoxifen occurs in a large proportion of patients with oestrogen receptor-positive (ER+) breast cancer and is…”
Get full text